The Global In Situ Hybridization Market will Hit $1.8 Billion by 2028, at a CAGR of 6.9%

In Situ Hybridization Market Growth, Trends and Report Highlights

According to a new report, published by KBV research, The Global In Situ Hybridization Market size is expected to reach $1.8 billion by 2028, rising at a market growth of 6.9% CAGR during the forecast period.

The Chromogenic In Situ Hybridization (CISH) segment is showcasing a CAGR of 9.3% during (2022 - 2028). CISH is a new area of study. It is anticipated to be a practical, affordable, and reliable alternative to FISH. This method combines immunohistochemistry with ISH (IHC). CISH probes may be identified with a bright-field microscope since they are digoxigenin- or biotin-labeled. As was already indicated, CISH is less expensive than FISH and is used as a bright-field microscope rather than a fluorescence microscope.

The Research & Diagnostic Laboratories segment acquired maximum revenue share in the Global In Situ Hybridization Market by End-use in 2021 thereby, achieving a market value of $857.3 million by 2028. Emerging clinical uses of ISH, such as prenatal diagnostics and gene expression, are expected to increase this market's growth potential. Growing awareness among pathologists and the desire for quick and accurate diagnostic methods also contribute to the industry's expansion. One of the key reasons accelerating the adoption of ISH is the clinical urgency to meet the diagnostic demands of emerging nations.

The Cytogenetics segment has shown the growth rate of 7.1% during (2022 - 2028). Cytogenetics studies chromosomal alterations in tissue, blood, or bone marrow samples, such as damaged, missing, altered, or additional chromosomes. FISH is becoming more and more significant in several scientific fields, including cytogenetics. Due to the potential advantages of FISH in cytogenetics, the market in this category will expand considerably.

The Instruments segment is leading the Global In Situ Hybridization Market by Product in 2021 thereby, achieving a market value of $678.3 million by 2028. Due to the increasing demand for instruments from diagnostic and research labs, this market segment is anticipated to expand over the projected period. In addition, better microscopes and imaging systems are anticipated to be in higher demand due to the growing need for improved imaging of FISH, CISH, and ISH samples. Researchers and pathologists choose this equipment for in situ hybridization procedures because of potential advantages such as increased cost-efficiency, simplicity of use, and mobility.

The RNA segment is poisd to grow at a CAGR of 8.6% during (2022 - 2028). Labeled complementary single-stranded RNA, commonly known as riboprobes, is another kind of probe used in ISH. It is anticipated that RNA probes will be more persistent than DNA probes. MiRNA ISH has seen tremendous improvement recently, including the introduction of Locked Nucleic Acid (LNA) probes. This lessens the background signal and improves the signal from the probe. As a result, healthcare experts may choose the best course of therapy by quickly identifying and validating infectious germs.

The North America market dominated the Global In Situ Hybridization Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $768.5 million by 2028, growing at a CAGR of 6.3 % during the forecast period. The Europe market is showcasing a CAGR of 6.5% during (2022 - 2028). Additionally, The Asia Pacific market woulds witness a CAGR of 7.8% during (2022 - 2028).

Full Report: https://www.kbvresearch.com/in-situ-hybridization-market/

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Thermo Fisher Scientific, Inc., Abbott Laboratories, PerkinElmer, Inc., Agilent Technologies, Inc., Merck Group, Bio-Rad Laboratories, Inc., Bio-Techne Corporation (Advanced Cell Diagnostics, Inc.), Danaher Corporation (Leica Biosystems), F. Hoffmann-La Roche Ltd., and Neogenomics, Inc.

Global In Situ Hybridization Market Segmentation

By Technology

• Fluorescent In Situ Hybridization (FISH)
• Chromogenic In Situ Hybridization (CISH)

By End Use

• Research & Diagnostic Laboratories
• Academic Institutes
• CROs
• Others

By Application

• Cancer
• Cytogenetics
• Developmental Biology
• Infectious Diseases
• Others

By Product

• Instruments
• Kits & Probes
• Software
• Services

By Probe

• DNA
• RNA

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Companies Profiled

• Thermo Fisher Scientific, Inc.
• Abbott Laboratories
• PerkinElmer, Inc.
• Agilent Technologies, Inc.
• Merck Group
• Bio-Rad Laboratories, Inc.
• Bio-Techne Corporation (Advanced Cell Diagnostics, Inc.)
• Danaher Corporation (Leica Biosystems)
• F.Hoffmann-La Roche Ltd.
• Neogenomics, Inc.

Related Reports:

North America In Situ Hybridization Market Size Report 2028

• January-2023
• 96 Pages

LAMEA In Situ Hybridization Market Size & Share to 2022-2028

• January-2023
• 113 Pages

Europe In Situ Hybridization Market Size & Forecast, 2028

• January-2023
• 113 Pages

Asia Pacific In Situ Hybridization Market Size Report 2028

• January-2023
• 113 Pages